CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
North China Pharmaceutical, Limited Company Snapshot
North China Pharmaceutical, Limited operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares North China Pharmaceutical, Limited with three other companies in this sector in China: Livzon Pharmaceutical Group Incorporated (2016 sales of 7.65 billion Chinese Renmimbi [US$1.11 billion] of which 42% was Western Medicine), Chongqing Taiji Industry (Group) (7.78 billion Chinese Renmimbi [US$1.13 billion] of which 52% was Trading), and Sichuan Kelun Pharmaceutical Company Limited (8.57 billion Chinese Renmimbi [US$1.24 billion] of which 96% was Medical and Pharmaceutical Products).

Sales Analysis. During the year ended December of 2016, sales at North China Pharmaceutical, Limited were 8.08 billion Chinese Renmimbi (US$1.17 billion). This is an increase of 2.3% versus 2015, when the company's sales were 7.90 billion Chinese Renmimbi. Despite this increase, sales are still well below the level achieved in 2014, when North China Pharmaceutical, Limited reported sales of 9.40 billion Chinese Renmimbi. Sales of Biopharmacy saw an increase that was more than double the company's growth rate: sales were up 28.7% in 2016, from 237.74 million Chinese Renmimbi to 305.87 million Chinese Renmimbi. North China Pharmaceutical, Limited also saw significant increases in sales in Chemical Preparation Medicine (up 10.4% to 3.46 billion Chinese Renmimbi) and Medicine and Other Logistics Trade (up 9.7% to 2.20 billion Chinese Renmimbi) . Not all segments of North China Pharmaceutical, Limited experienced an increase in sales in 2016: sales of Medical Intermediate fell 34.7% to 170.68 million Chinese Renmimbi. (However, this segment's sales were only a very small portion of the company's overall sales). North China Pharmaceutical, Limited also experienced decreases in sales in Chemical Raw Medicine (down 15.7% to 1.66 billion Chinese Renmimbi) and Other (down 13.1% to 92.89 million Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
North China Pharmaceutical, Limited
  Stock Performance Chart for North China Pharmaceutical, Limited
 
  Stock Data: Recent Stock Performance:
  Current Price (5/19/2017): 5.91
(Figures in Chinese Renmimbi)
1 Week 4.4%   13 Weeks -4.8%  
4 Weeks -5.3%   52 Weeks -5.1%  
 
North China Pharmaceutical, Limited Key Data:
  Ticker: 600812 Country: China
  Exchanges: SHG Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2016 Sales 8,080,698,105
(Year Ending Jan 2017).
Employees: 10,886
  Currency: Chinese Renmimbi Market Cap: 9,638,055,948
  Fiscal Yr Ends: December Shares Outstanding: 1,630,804,729
  Share Type: A Gu Closely Held Shares: 914,862,975
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.